Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Biohaven Ltd. (BHVN – ...
Adjusted earnings for 2025 will be $5.75 to $6 a share, CVS said, while the average estimate of analysts surveyed by ...
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners ...
CVS's medical benefit ratio -- a closely-monitored metric tracking the premiums spent on medical care for insurance holders -- was 94.8%, down from a record high of 95.2% in the prior quarter. The ...
MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE: ANRO), currently trading at $3.11 and down nearly 26% over the past week, has announced the continuation of its Phase 2b clinical trial for ...
NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback